145 related articles for article (PubMed ID: 36226470)
41. Oral ulcers and sarcoid-like reaction in lymph nodes after cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma: a case report.
Ferreira MH; Bezinelli LM; Eduardo FP; Gobbi MF; Corrêa L; Schvartsman G
Einstein (Sao Paulo); 2022; 20():eRC6367. PubMed ID: 35303053
[TBL] [Abstract][Full Text] [Related]
42. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Hernández-Guerrero T; Doger B; Moreno V
Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
[TBL] [Abstract][Full Text] [Related]
43. Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.
Piccerillo A; El Hachem M; De Vito R; De Luca EV; Peris K
JAMA Dermatol; 2020 Jun; 156(6):708-710. PubMed ID: 32320041
[No Abstract] [Full Text] [Related]
44. Cemiplimab removed from reimbursable drugs in France.
Pham F; Reynaud B; Favier B; Darnis S; Amini-Adle M
Eur J Cancer; 2021 May; 149():11-13. PubMed ID: 33812142
[No Abstract] [Full Text] [Related]
45. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma.
Valentin J; Gérard E; Ferte T; Prey S; Dousset L; Dutriaux C; Beylot-Barry M; Pham-Ledard A
J Geriatr Oncol; 2021 Sep; 12(7):1110-1113. PubMed ID: 33736973
[TBL] [Abstract][Full Text] [Related]
46. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.
Deinlein T; Lax SF; Schwarz T; Giuffrida R; Schmid-Zalaudek K; Zalaudek I
Eur J Cancer; 2017 Sep; 83():99-102. PubMed ID: 28734147
[No Abstract] [Full Text] [Related]
47. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
[No Abstract] [Full Text] [Related]
48. Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.
Zalaudek I; Corneli P; Vernoni S; Fedele D; Papa G; Conforti C; Retrosi C; Vezzoni R; Fagotti S; Longone M; Farinazzo E; di Meo N; Pizzichetta MA
Dermatol Ther; 2019 Nov; 32(6):e13107. PubMed ID: 31595596
[No Abstract] [Full Text] [Related]
49. Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma.
Maredia H; Simkin D; Soni A; Loss MJ
Int J Dermatol; 2020 May; 59(5):e141-e142. PubMed ID: 31670381
[No Abstract] [Full Text] [Related]
50. Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients.
Boyd K; Shea SM; Patterson J
Wien Med Wochenschr; 2013 Aug; 163(15-16):372-5. PubMed ID: 23800851
[TBL] [Abstract][Full Text] [Related]
51. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
Venkatesh S; Al-Haseni A; Sahni D
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
[TBL] [Abstract][Full Text] [Related]
52. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp.
Paoluzzi L; Ow TJ
Curr Oncol; 2021 Jan; 28(1):574-580. PubMed ID: 33477979
[TBL] [Abstract][Full Text] [Related]
53. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
Tran DC; Colevas AD; Chang AL
JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
[No Abstract] [Full Text] [Related]
54. Successful treatment of recurrent advanced cutaneous squamous cell carcinoma with cemiplimab.
Cervantes JA; Fox MC
Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147669
[TBL] [Abstract][Full Text] [Related]
55. Development of cutaneous squamous cell carcinoma during pembrolizumab therapy.
Mizutani K; Nakanishi T; Ikejiri M; Yuasa H; Matsushima Y; Kondo M; Nakai Y; Habe K; Nakatani K; Yamanaka K
J Dermatol; 2021 Jan; 48(1):e7-e8. PubMed ID: 32940367
[No Abstract] [Full Text] [Related]
56. Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma.
Hennemann A; Collonge Rame MA; Puzenat E; Ged C; Harbon S; Aubin F; Nardin C
Acta Oncol; 2022 Sep; 61(9):1140-1142. PubMed ID: 35950634
[No Abstract] [Full Text] [Related]
57. Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response.
Sweeney KJ; Tetzlaff MT; Vega F; Gillenwater A; Zuo Z; Gross N; Nagarajan P; Wargo J; Nelson K; Prieto VG; Torres-Cabala CA; Curry JL
J Cutan Pathol; 2021 May; 48(5):674-679. PubMed ID: 33399228
[TBL] [Abstract][Full Text] [Related]
58. Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab.
Jouneghani NS; Phillip J; Dasanu CA
J Oncol Pharm Pract; 2022 Apr; 28(3):722-724. PubMed ID: 34791931
[TBL] [Abstract][Full Text] [Related]
59. Complete response of advanced cutaneous squamous cell and basal cell carcinomas with sequential cemiplimab and sonidegib therapy.
Weis J; Grote C; Weichenthal M; Hauschild A
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():66-69. PubMed ID: 34855253
[TBL] [Abstract][Full Text] [Related]
60. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic.
Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M
Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
